Obesity in patients with non-ST-segment elevation acute coronary syndromes: Results from the SYNERGY trial
Kenneth W. Mahaffey(Cardiovascular Institute of the South), Robert M. Califf(Duke University), Elliott M. Antman(Brigham and Women's Hospital), Glenn N. Levine(American College of Cardiology), Philip E. Aylward(Flinders Medical Centre), Shaun G. Goodman(University of Toronto), John Ducas(St. Boniface Hospital), Richard L. Gallo(University of California San Diego), Anatoly Langer(University of Toronto), Harvey D. White(University of Auckland), Sarah A. Spinler(Unknown), James J. Ferguson(Brigham and Women's Hospital), Richard C. Becker(University of Cincinnati), Jacques Col(Cliniques Universitaires Saint-Luc), Simon T. Tonev
Cited by 54
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k